Based on my analysis of the earnings transcript, I would project a neutral to slightly positive short-term impact on J&J's stock price. The key positives include solid Q1 earnings that beat estimates ($1.26 vs $1.20 consensus), successful launch of ZYRTEC OTC, and improved operating margins from cost restructuring. However, this is balanced by concerns about slowing procedure volumes in medical devices, ongoing generic competition in pharma, and relatively modest 1-2% operational growth guidance for 2008. Management's tone was cautiously optimistic while acknowledging near-term headwinds. The diversity of J&J's business helps provide stability but may limit upside catalysts in the very short term.

[0]